MULTIPLE MARKERS OF AUTOIMMUNITY AMONG APPARENT NIDDM SUBJECTS IN THE FUSION STUDY. William A. Hagopian*1, Timo Valle2, Richard M. Watanabe3,4, Elizabeth R. Hauser4, Richard N. Bergman3, Eva Tuomilehto-Wolf2, Jaakko Tuomilehto2, Soumitra Ghosh5, Francis Collins5, Michael Boehnke4, and the Finland-United States Investigation of NIDDM Genetics (FUSION) Study Group. 1Dept. Medicine, Univ. Washington, Seattle WA, 2Dept. Epidemiology, National Public Health Institute, Helsinki FINLAND, 3Dept. Physiology, USC, Los Angeles CA, 4Dept. Biostatistics, Univ. Michigan, Ann Arbor MI, 5NCHGR, Bethesda MD. Autoantibodies to the two major identified ICA antigens, glutamate decarboxylase (GAD) and the beta-cell protein tyrosine phosphatase ICA512, were measured in plasma samples from 1084 Finnish NIDDM patients (WHO criteria, aged 35-60 years) sampled a mean of 11 years after diagnosis. A total of 59/1084 (5.4%) were positive for GADab (cutoff = mean + 3SD of 104 Swedish, Finnish and American controls). Fifty-seven GADab positive samples, and 41 samples negative for GADab, were tested for antibodies to ICA512 (cutoff = mean + 3SD of 104 Swedish, Finnish and American controls). Only 11/57 (19.3%) of the GADab positive samples, and 0/41 of the GADab negative samples, had autoantibodies to ICA512 (p=0.001, Fisher's exact test). Of subjects positive for both autoantibodies, ICA512ab levels were highly correlated to GADab levels (r=0.87, p<0.001). No relationship between presence of either marker and subject age nor time of sampling after diagnosis was found, but fasting C-peptide and fasting insulin were both significantly lower in those with GADab (p<0.001 and p=0.008, respectively) and those with ICA512ab (p=0.007 and p=0.015, respectively) versus those without these autoantibodies. We conclude that although ICA512ab may be less sensitive than GADab for detecting autoimmunity in NIDDM patients sampled long after onset, both autoantibodies are associated with low endogenous insulin secretion among these subjects.